Charles Schwab
ACET icon

Charles Schwab’s Adicet Bio ACET Stock Holding History

Charles Schwab’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,875
Closed -$18.3K – 3456
2025
Q2 		$18.3K Hold
1,875
– – ﹤0.01% 3489
2025
Q1 		$22.6K Hold
1,875
– – ﹤0.01% 3455
2024
Q4 		$28.9K Sell
1,875
-3
-0.2% -$57 ﹤0.01% 3474
2024
Q3 		$43.3K Sell
1,878
-7
-0.4% -$157 ﹤0.01% 3427
2024
Q2 		$36.5K Sell
1,885
-7,495
-80% -$201K ﹤0.01% 3551
2024
Q1 		$353K Buy
9,380
+5,039
+116% +$208K ﹤0.01% 3139
2023
Q4 		$131K Hold
4,341
– – ﹤0.01% 3325
2023
Q3 		$95.2K Sell
4,341
-828
-16% -$29.2K ﹤0.01% 3359
2023
Q2 		$201K Buy
5,169
+96
+2% +$8.47K ﹤0.01% 3308
2023
Q1 		$468K Hold
5,073
– – ﹤0.01% 2972
2022
Q4 		$726K Buy
5,073
+366
+8% +$91.3K ﹤0.01% 2889
2022
Q3 		$1.07M Buy
4,707
+239
+5% +$60.7K ﹤0.01% 2771
2022
Q2 		$1.04M Buy
4,468
+293
+7% +$64.3K ﹤0.01% 2775
2022
Q1 		$1.33M Buy
4,175
+945
+29% +$217K ﹤0.01% 2765
2021
Q4 		$905K Buy
3,230
+132
+4% +$22.7K ﹤0.01% 2954
2021
Q3 		$389K Hold
3,098
– – ﹤0.01% 3211
2021
Q2 		$510K Buy
+3,098
New +$631K ﹤0.01% 3164
2020
Q3 		– Sell
-561
Closed -$136K – 3345
2020
Q2 		$136K Sell
561
-216
-28% -$42.4K ﹤0.01% 3218
2020
Q1 		$90K Buy
777
+12
+2% +$1.78K ﹤0.01% 3114
2019
Q4 		$128K Sell
765
-94
-11% -$47.6K ﹤0.01% 3084
2019
Q3 		$851K Buy
859
+40
+5% +$44.7K ﹤0.01% 2618
2019
Q2 		$936K Buy
819
+229
+39% +$208K ﹤0.01% 2594
2019
Q1 		$451K Buy
590
+258
+78% +$234K ﹤0.01% 2794
2018
Q4 		$321K Sell
332
-6
-2% -$7.9K ﹤0.01% 2911
2018
Q3 		$573K Buy
338
+78
+30% +$102K ﹤0.01% 2787
2018
Q2 		$267K Buy
260
+9
+4% +$9.69K ﹤0.01% 3009
2018
Q1 		$270K Buy
+251
New +$461K ﹤0.01% 2909

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Charles Schwab's ACET Position: Q3 2025 in Review

Charles Schwab sold out of Adicet Bio (ACET) in Q3 2025, closing a stake of 1,875 shares — an estimated $18.3K sold.

Charles Schwab first reported a position in ACET in Q1 2018 and held it in 27 quarters. The position peaked at $1.33M in Q1 2022. 54 funds tracked by Wall St. Rank hold ACET as of Q3 2025.

  • Charles Schwab reported no remaining Adicet Bio position as of Q3 2025 after selling out during the quarter.
  • Charles Schwab sold 1,875 Adicet Bio shares in Q3 2025, an estimated $18.3K.
  • Charles Schwab first reported a position in Adicet Bio in Q1 2018 and held it in 27 quarters.
  • Charles Schwab's Adicet Bio position peaked at $1.33M in Q1 2022.
  • 54 funds tracked by Wall St. Rank held Adicet Bio as of Q3 2025.

Based on Charles Schwab's 13F filing for Q3 2025, filed 10 Nov 2025.